People who switched from obesity injections to Novo 's new Wegovy pill continued to lose weight after three months, according to an analysis of real-world data the company presented on Wednesday. Real-world studies evaluate associations and can't determine causality. But the results suggest that the Wegovy pill may improve upon the initial weight loss people experience on blockbuster injections rather than simply maintain it. It also suggests that patients may not need to take weekly shots like Wegovy and Zepbound forever, and can instead opt for more convenient treatments such as Novo's pill. Novo's analysis used data from Ro's telehealth platform on 194 patients with obesity or who were overweight, around 56% of whom were female.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.